SM
RNTX

Sabby Management’s Rein Therapeutics RNTX Stock Holding History

Sabby Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-27,495
Closed -$368K – 91
2019
Q3 		$368K Sell
27,495
-23,062
-46% -$319K 0.2% 52
2019
Q2 		$728K Buy
+50,557
New +$1.33M 0.92% 23

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
IWAG
Integer Wealth Advisors Group Cartersville, Georgia $184M AUM 62.15% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return

Sabby Management's RNTX Position: Q4 2019 in Review

Sabby Management sold out of Rein Therapeutics (RNTX) in Q4 2019, closing a stake of 27,495 shares — an estimated $368K sold.

Sabby Management first reported a position in RNTX in Q2 2019 and held it in 2 quarters. The position peaked at $728K in Q2 2019. 17 funds tracked by Wall St. Rank hold RNTX as of Q4 2019.

  • Sabby Management reported no remaining Rein Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sabby Management sold 27,495 Rein Therapeutics shares in Q4 2019, an estimated $368K.
  • Sabby Management first reported a position in Rein Therapeutics in Q2 2019 and held it in 2 quarters.
  • Sabby Management's Rein Therapeutics position peaked at $728K in Q2 2019.
  • 17 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2019.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.